Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 1, 2014, Pages 151-156

  Na, Gun Hyung ^a   Kim, Dong Goo ^a   Han, Jae Hyun ^a   Kim, Eun Young ^a   Lee, Soo Ho ^a   Hong, Tae Ho ^a   You, Young Kyoung ^a   Choi, Jong Young ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Entecavir; Hepatitis B immunoglobulin; Hepatitis B virus; Hepatocelluar carcinoma; Liver transplantation; Nucleos(t)ide analog

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; CYCLOSPORIN; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; VIRUS DNA;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR;

ENTECAVIR; HEPATITIS B IMMUNOGLOBULIN; HEPATITIS B VIRUS; HEPATOCELLUAR CARCINOMA; LIVER TRANSPLANTATION; NUCLEOS(T)IDE ANALOG;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; NUCLEOTIDES; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84897584879     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12403     Document Type: Article

References (23)

1. Rekkedal G. [WHO world health report 1997.] Tidsskr. Sykepl. 1997; 85: 37-39.
2. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-1195.
3. Samuel D, Muller R, Alexander G etal. Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med. 1993; 329: 1842-1847.
4. Steinmüller T, Seehofer D, Rayes N etal. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528-1535.
5. Fung J, Cheung C, Chan SC etal. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141: 1212-1219.
6. Weber NK, Forman LM, Trotter JF. HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients. Dig. Dis. Sci. 2010; 55: 505-509.
7. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 2000; 6: 429-433.
8. Degertekin B, Han SH, Keeffe EB etal. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am. J. Transplant. 2010; 10: 1823-1833.
9. Gane EJ, Angus PW, Strasser S etal. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937.
10. Zheng S, Chen Y, Liang T etal. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl. 2006; 12: 253-258.
11. Wesdorp DJ, Knoester M, Coenraad MJ, Braat AE, Claas EC, van Hoek B. One year results or tenofovir and emtricitabine without HBIG to prevent hepatitis B recurrence after liver transplantation. J. Hepatol. 2012; 56: S96-97.
12. Stravitz RT, Shiffman ML, Kimmel M etal. Substitution of tenofovir/emtricitabine for hepatitis B immune globulin prevents recurrence of hepatitis B after liver transplantation. Liver Int. 2012; 32: 1138-1145.
13. Wadhawan M, Vij V, Goyal N, Dargan P, Rastogi M, Vasu F. Living related liver transplant (LRLT) in HBV DNA negative cirrhosis without hepatitis B immune globulin (HBIG). Hepatol. Int. 2011; 5: S38.
14. Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl. 2013; 19: 268-274.
15. Fung J, Chan SC, Cheung C etal. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am. J. Gastroenterol. 2013; 108: 942-948.
16. Laryea MA, Watt KD. Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation. Liver Transpl. 2012; 18: 514-523.
17. Seehofer D, Rayes N, Berg T etal. Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. Transpl. Int. 2000; 13: 290-296.
18. Saab S, Yeganeh M, Nguyen K etal. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl. 2009; 15: 1525-1534.
19. Sung JJ, Wong ML, Bowden S etal. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890-1897.
20. Wong DK, Yuen MF, Poon RT, Yuen JC, Fung J, Lai CL. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J. Hepatol. 2006; 45: 553-559.
21. Faria LC, Gigou M, Roque-Afonso AM etal. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008; 134: 1890-1899.
22. Schiff E, Lai CL, Hadziyannis S etal. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007; 13: 349-360.
23. Akyildiz M, Karasu Z, Zeytunlu M, Aydin U, Ozacar T, Kilic M. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J. Gastroenterol. Hepatol. 2007; 22: 2130-2134.